C.R. Bard

C.R. Bard

C.R. Bard was an American medical device company founded in 1907 that developed and manufactured specialty devices for vascular surgery, urology, oncology, and general surgery. Over its history the firm engaged with hospitals, clinics, and regulatory bodies such as the United States Food and Drug Administration, expanded through acquisitions, and was acquired by Becton, Dickinson and Company in 2017. The company operated global manufacturing sites and sales organizations serving markets across North America, Europe, and Asia-Pacific.

History

Founded in 1907 by Charles Russell Bard in Hooksett, the company began producing sterile surgical tools and evolved through the 20th century amid developments in World War I and World War II that increased demand for single-use devices. During the postwar era Bard expanded its portfolio through internal innovation and strategic purchases, interacting with firms such as Angiotech Pharmaceuticals, Allied Healthcare Products, and RITA Medical Systems. The company listed on the New York Stock Exchange and navigated regulatory shifts instituted by the Federal Food, Drug, and Cosmetic Act and subsequent Medical Device Amendments overseen by the United States Food and Drug Administration. In the 2000s Bard grew through acquisitions including Cook Medical-adjacent technologies and smaller specialty-device companies, culminating in its acquisition by Becton, Dickinson and Company in 2017, a transaction reviewed by antitrust authorities in the United States Department of Justice and other international regulators.

Products and Technologies

Bard's product lines included venous access devices such as peripherally inserted central catheters (PICC) and implantable ports used by oncology providers like Memorial Sloan Kettering Cancer Center and Mayo Clinic. The company produced urology products including catheters and stents used in procedures at institutions such as Cleveland Clinic and Johns Hopkins Hospital. Vascular intervention offerings encompassed angiographic catheters, introducers, and closure devices used in catheterization labs like those at Massachusetts General Hospital and Mount Sinai Health System. Bard also manufactured surgical mesh and implantable devices implicated in pelvic surgery performed by specialists affiliated with Kaiser Permanente and Montefiore Medical Center. Its technologies intersected with clinical practice guidelines from organizations such as the American College of Surgeons and the Society of Interventional Radiology.

Legal Issues and Recalls

The company faced extensive litigation and regulatory scrutiny over certain products, including transvaginal mesh and ureteral stents, resulting in multidistrict litigation in venues like the United States District Court for the District of Rhode Island and settlement negotiations overseen by federal judges and litigators from firms that have represented plaintiffs in mass torts such as Weitz & Luxenberg and Fazel-type practices. Bard issued recalls coordinated with the United States Food and Drug Administration for specific lots of products, and encountered verdicts and settlements addressing alleged device failures and complications that implicated healthcare systems including Partners HealthCare and Trinity Health. The legal outcomes influenced industry-wide compliance standards and prompted enhanced post-market surveillance recommended by agencies such as the European Medicines Agency and Health Canada.

Corporate Structure and Operations

Prior to its acquisition, Bard organized into business units covering vascular, urology, oncology, and surgical specialties with global sales forces operating in markets such as Germany, France, Japan, and Brazil. The company maintained manufacturing and R&D sites in the United States, including Murray Hill, New Jersey, and international facilities that adhered to standards set by regulators like the International Organization for Standardization and inspectors from the United States Food and Drug Administration. Corporate governance featured a board of directors with ties to companies such as Johnson & Johnson, Medtronic, and Pfizer, and investor relations engaged institutional shareholders including Vanguard Group and BlackRock. Bard’s supply chain relied on contract manufacturers and distributors comparable to partners used across the medical device sector, and its sales model combined direct sales to hospital systems and distribution through group purchasing organizations like Premier, Inc..

Research, Development, and Acquisitions

Bard invested in clinical research and product development collaborating with academic centers including Stanford University School of Medicine, University of California, San Francisco, and University of Pennsylvania Health System to run trials and registries. The company acquired niche firms to broaden its portfolio, integrating technologies from specialty device companies and engaging in licensing agreements with biotechnology firms and startups participating in venture capital rounds led by investors such as Sequoia Capital-style funds and corporate venture arms. Post-acquisition, Bard’s pipelines and assets were integrated into Becton, Dickinson and Company’s R&D strategy, aligning with other industry consolidation moves involving firms like Abbott Laboratories and Boston Scientific.

Category:Medical device companies